Eudragit RS100 nanoparticles for sustained release of Cefpodoxime Proxetil: preparation, pharmaceutical characterization, and in-vitro drug release studies
Nanomedicine Journal · 2026-01 · 13 (1) · 210-223
DOI: 10.22038/nmj.2025.82111.2045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nanomedicine Journal, 2026-01. Verfasst von Jaya Verma und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Objective(s): The primary objective of this study was to develop a sustained-release formulation of cefpodoxime proxetil (CP) using the polymer Eudragit RS 100 (ERS100).Materials and Methods: Pluronic F127 (PF127) was incorporated as an amphiphilic surfactant to enhance product stability. Preformulation evaluations, including UV-visible spectroscopy and Fourier-transform infrared spectroscopy (FTIR), were performed to assess the compatibility of the drug, polymer, and their 1:1 mixture. Nanoparticles were formulated using the solvent evaporation technique, followed by continuous stirring of the emulsion during the removal of the organic solvent.
Results
The optimized formulation exhibited a particle size of less than 200 nm and an entrapment efficiency of 81.45 ± 0.891% for CP. In vitro drug release studies revealed sustained-release behavior, with the release kinetics best fitting the Higuchi (R² = 0.9757) and Hixson–Crowell (R² = 0.9707) models. Stability studies confirmed compliance with ICH guidelines regarding temperature and humidity conditions. These findings underscore the potential of CP-loaded nanoparticles as efficient carriers for sustained drug delivery, particularly targeting lung tissues.
Conclusion
The developed ERS100-based CP nanoparticles offer promising therapeutic benefits, including improved patient adherence through extended drug release intervals.
Schlagwörter
Zitieren
APA
Verma, J., Shekhar, S., ,, M., Jhawat, V., Chauhan, M., Sonali, ,, & Singh, R. P. (2026). Eudragit RS100 nanoparticles for sustained release of Cefpodoxime Proxetil: preparation, pharmaceutical characterization, and in-vitro drug release studies. Nanomedicine Journal, 13(1), 210-223. https://doi.org/10.22038/nmj.2025.82111.2045
Vancouver
Verma J, Shekhar S, , M, Jhawat V, Chauhan M, Sonali, et al. Eudragit RS100 nanoparticles for sustained release of Cefpodoxime Proxetil: preparation, pharmaceutical characterization, and in-vitro drug release studies. Nanomedicine Journal. 2026;13(1):210-223. doi:10.22038/nmj.2025.82111.2045
BibTeX
@article{Verma2026,
author = {Verma, Jaya and Shekhar, Saurabh and ,, Monika and Jhawat, Vikas and Chauhan, Mahima and Sonali and , and Singh, Rahul Pratap},
title = {Eudragit RS100 nanoparticles for sustained release of Cefpodoxime Proxetil: preparation, pharmaceutical characterization, and in-vitro drug release studies},
journal = {Nanomedicine Journal},
year = {2026},
volume = {13},
number = {1},
pages = {210--223},
doi = {10.22038/nmj.2025.82111.2045}
}
EUVIMED